Ulrich Pehl

Darmstadt, HE 64293, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1.

Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1.

Journal: Journal of medicinal chemistry

Published: December 08, 2025

Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Journal: Journal of medicinal chemistry

Published: September 17, 2025

Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Journal: Nucleic acids research

Published: June 27, 2025

Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros.

Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros.

Journal: Journal of medicinal chemistry

Published: January 27, 2022

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

Journal: Molecular cancer therapeutics

Published: November 25, 2021

Molecular basis of human ATM kinase inhibition.

Molecular basis of human ATM kinase inhibition.

Journal: Nature structural & molecular biology

Published: February 03, 2021

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.

Journal: Molecular cancer therapeutics

Published: July 30, 2019

Integration of an In Situ MALDI-Based High-Throughput Screening Process: A Case Study with Receptor Tyrosine Kinase c-MET.

Integration of an In Situ MALDI-Based High-Throughput Screening Process: A Case Study with Receptor Tyrosine Kinase c-MET.

Journal: SLAS discovery : advancing life sciences R & D

Published: August 19, 2017

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: December 18, 2014

EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.

EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 05, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026